Xeris Pharmaceuticals Stock Revenue
| XERS Stock | USD 4.56 0.01 0.22% |
Xeris Pharmaceuticals fundamentals help investors to digest information that contributes to Xeris Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Xeris Stock. The fundamental analysis module provides a way to measure Xeris Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xeris Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 203.1 M | 213.2 M |
Xeris | Revenue |
Xeris Pharmaceuticals Company Revenue Analysis
Xeris Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Xeris Pharmaceuticals Revenue | 203.07 M |
Most of Xeris Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xeris Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Xeris
Projected quarterly revenue analysis of Xeris Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Xeris Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Xeris Pharmaceuticals' stock price.
Xeris Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Xeris Pharmaceuticals is extremely important. It helps to project a fair market value of Xeris Stock properly, considering its historical fundamentals such as Revenue. Since Xeris Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Xeris Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Xeris Pharmaceuticals' interrelated accounts and indicators.
| 0.8 | 0.85 | -0.38 | 0.76 | 0.91 | ||
| 0.8 | 0.99 | -0.3 | 0.64 | 0.75 | ||
| 0.85 | 0.99 | -0.32 | 0.69 | 0.8 | ||
| -0.38 | -0.3 | -0.32 | -0.44 | -0.71 | ||
| 0.76 | 0.64 | 0.69 | -0.44 | 0.81 | ||
| 0.91 | 0.75 | 0.8 | -0.71 | 0.81 |
Click cells to compare fundamentals
Xeris Revenue Historical Pattern
Today, most investors in Xeris Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Xeris Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Xeris Pharmaceuticals revenue as a starting point in their analysis.
Xeris Pharmaceuticals Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Xeris Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Xeris Pharmaceuticals reported 203.07 M of revenue. This is 97.34% lower than that of the Pharmaceuticals sector and 72.67% lower than that of the Health Care industry. The revenue for all United States stocks is 97.85% higher than that of the company.
Xeris Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xeris Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xeris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xeris Pharmaceuticals by comparing valuation metrics of similar companies.Xeris Pharmaceuticals is currently under evaluation in revenue category among its peers.
Xeris Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Xeris Pharmaceuticals from analyzing Xeris Pharmaceuticals' financial statements. These drivers represent accounts that assess Xeris Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Xeris Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 209.8M | 231.5M | 180.4M | 323.5M | 497.6M | 522.4M | |
| Enterprise Value | 230.6M | 307.6M | 256.5M | 485.3M | 697.4M | 732.3M |
Xeris Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xeris Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xeris Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Xeris Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Xeris Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Xeris Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Xeris Pharmaceuticals' value.| Shares | Ubs Group Ag | 2024-12-31 | 1.7 M | Goldman Sachs Group Inc | 2024-12-31 | 1.6 M | D. E. Shaw & Co Lp | 2024-12-31 | 1.4 M | Northern Trust Corp | 2024-12-31 | 1.2 M | Jpmorgan Chase & Co | 2024-12-31 | 1 M | Bank Of America Corp | 2024-12-31 | 991.7 K | Aqr Capital Management Llc | 2024-12-31 | 834.9 K | Citadel Advisors Llc | 2024-12-31 | 833.3 K | Centerbook Partners Lp | 2024-12-31 | 690.1 K | Blackrock Inc | 2024-12-31 | 10.8 M | Vanguard Group Inc | 2024-12-31 | 7.9 M |
Xeris Fundamentals
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.0533 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 874.08 M | ||||
| Shares Outstanding | 153.94 M | ||||
| Shares Owned By Insiders | 3.99 % | ||||
| Shares Owned By Institutions | 42.86 % | ||||
| Number Of Shares Shorted | 10.27 M | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 3.46 X | ||||
| Revenue | 203.07 M | ||||
| Gross Profit | 166.24 M | ||||
| EBITDA | (13.99 M) | ||||
| Net Income | (54.84 M) | ||||
| Cash And Equivalents | 111.55 M | ||||
| Cash Per Share | 0.82 X | ||||
| Total Debt | 271.45 M | ||||
| Debt To Equity | 1.87 % | ||||
| Current Ratio | 2.50 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (36.98 M) | ||||
| Short Ratio | 5.88 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Target Price | 6.08 | ||||
| Number Of Employees | 394 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 703.51 M | ||||
| Total Asset | 323.06 M | ||||
| Retained Earnings | (671.86 M) | ||||
| Working Capital | 67.22 M | ||||
| Net Asset | 323.06 M |
About Xeris Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xeris Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.